CanVirex is a next generation immunotherapeutics company founded as a spin-off from Heidelberg University Hospital and National Center for Tumor Diseases. CanVirex develops viro-immunotherapeutics for treatment of cancer and platform for vaccination against infectious diseases, specifically COVID-19.
- https://www.canvirex.com
- +41 61 515 07 70
- office@canvirex.com
- Dr. Werner Tschollar